In the name of of Allah the Merciful

New Drug Development for Known and Emerging Viruses

Helga Rübsamen-Schaeff, Helmut Buschmann, 3527343377, 9783527343379, B09MYGRFTP, 978-3527343379

100,000 Toman
The desired product is not available.

English | 2022 | PDF

  • {{value}}
کمی صبر کنید...

Discusses how to fight Ebola, SARS Corona, and other known or emerging human viruses by building on the successes in antiviral therapy of the past decades 

Written by leading medicinal chemists from academia and industry, this book discusses the entire field of antiviral drug discovery and development from a medicinal chemistry perspective, focusing on antiviral drugs, targets, and viral disease mechanisms. It provides an outlook on emerging pathogens such as Ebola, Zika, West Nile, Lassa, and includes a chapter on SARS Coronoavirus-2 causing the present pandemic.  

New Drug Development for Known and Emerging Viruses describes the discovery and development process for antiviral agents for different classes of viruses and targets based on the experiences from the nine human viruses for which approved drugs are on the market (HIV, HCV, Influenza, RSV, HBV, HPV, HCMV, HSV, and VZV). It covers the properties and potential of 20 classes of currently approved antivirals, including combination drugs, and looks at novel antiviral strategies against emerging viruses. 

    • Covers the entire field of antiviral drug discovery and development  
    • Addresses the need for antiviral drugs to combat major health threats such as Ebola, Zika, West Nile, and SARS Coronavirus-2 
    • Summarizes the successes of the past 15 years in developing ground-breaking medicines against 9 major human viruses, both from the medicinal chemistry and the pharmacological angle 
    • Discusses practical and strategic challenges in the drug discovery and development process, including screening technologies, latency, and toxicity issues 

New Developments in Antiviral Drugs is an important book for medicinal chemists, pharmaceutical chemists, virologists, and epidemiologists, and will be of great interest to those in the pharmaceutical industry and public health agencies.